Becaplermin biosimilar - Adocia

Drug Profile

Becaplermin biosimilar - Adocia

Alternative Names: BC-PDGF-BB; BioChaperone® PDGF-BB; PDGF-BB biosimilar - Adocia

Latest Information Update: 23 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adocia
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Burns; Diabetic foot ulcer; Pressure ulcer; Varicose ulcer

Highest Development Phases

  • Discontinued Burns; Diabetic foot ulcer; Pressure ulcer; Varicose ulcer

Most Recent Events

  • 22 Sep 2016 Discontinued - Phase-III for Diabetic foot ulcer in India (Topical)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Burns in France (Topical, Spray)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pressure-ulcer in France (Topical, Spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top